Discounted Cash Flow Rating

Strong Sell

Return on Equity Rating

Sell

Debt to Equity Rating

Strong Buy

Price to Earnings Rating

Strong Buy

Analyst Rating

Neutral

Simple Moving Average

Neutral

Exponential Moving Average

Neutral

Relative Strength Index

Neutral

Standard Deviation

Strong Buy

Williams %R

Strong Buy

Average Directional Index

Sell

Insider Trading

Buy

Wall Street Data Solutions Rating

Neutral

B

Arcutis Biotherapeutics, Inc. Common Stock (ARQT)

Pharmaceutical Preparations

https://www.arcutis.com

Arcutis Biotherapeutics Inc is a medical dermatology company. It is developing treatments for patients with immune-mediated dermatological diseases and conditions. It is leveraging recent advances in immunology and inflammation to develop differentiated therapies against biologically validated targets to solve persistent treatment challenges in serious diseases of the skin. The company's lead product candidate ZORYVE roflumilast cream, has successfully completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population.

3027 TOWNSGATE ROAD, SUITE 300
WESTLAKE VILLAGE, CA

Current Price

---.--

% Change Today

0.00%

Change Amt. Today

0.00

Active Status

Active

Listing Date

01/31/2020

Market Cap

975,311,700

Shares Outstanding

96,790,000

Weighted SO

96,792,606

Total Employees

N/A

Upcoming Earnings

08/13/2024

Beta

1.1780

Last Div

0.0000

Range

1.76-13.17

Chg

-0.0750

Avg Vol

2669735

Mkt Cap

975311700

Exch

NASDAQ

Country

US

Phone

805 418 5006

DCF Diff

10.1981

DCF

-1.7181

Div Yield

0.0000

P/S

7.3853

EV Multiple

-6.2401

P/FV

5.5803

Div Yield %

0.0000

P/E

-5.2340

PEG

-0.2094

Payout

0.0000

Current Ratio

8.4630

Quick Ratio

8.1927

Cash Ratio

1.6530

DSO

119.9816

DIO

489.6772

Op Cycle

609.6588

DPO

280.2238

CCC

329.4350

Gross Margin

0.9217

Op Margin

-1.3613

Pretax Margin

-1.4795

Net Margin

-1.5051

Eff Tax Rate

-0.0173

ROA

-0.4469

ROE

-1.4541

ROCE

-0.4570

NI/EBT

1.0173

EBT/EBIT

1.0869

EBIT/Rev

-1.3613

Debt Ratio

0.4600

D/E

1.0974

LT Debt/Cap

0.5223

Total Debt/Cap

0.5232

Int Coverage

-11.7368

CF/Debt

-0.8649

Equity Multi

2.3857

Rec Turnover

3.0421

Pay Turnover

1.3025

Inv Turnover

0.7454

FA Turnover

37.6245

Asset Turnover

0.2969

OCF/Share

-1.4330

FCF/Share

-1.4336

Cash/Share

2.9402

OCF/Sales

-1.3399

FCF/OCF

1.0004

CF Coverage

-0.8649

ST Coverage

-227.7349

CapEx Coverage

-2527.8571

Div&CapEx Cov

-2527.8571

P/BV

5.5803

P/B

5.5803

P/S

7.3853

P/E

-5.2340

P/FCF

-5.5096

P/OCF

-5.8792

P/CF

-5.8792

PEG

-0.2094

P/S

7.3853

EV Multiple

-6.2401

P/FV

5.5803

DPS

0.0000

Latest Headlines (EST)

GlobeNewswire Inc. Jan 14, 04:00 ZORYVE® (Roflumilast) Topical Foam, 0.3% Clears Seborrheic Dermatitis in Individuals Who Previously Reported an Inadequate Response to Topical Steroids GlobeNewswire Inc. Jan 14, 04:00 Majority of Individuals with Atopic Dermatitis Improved with Arcutis’ Roflumilast Cream 0.15% According to New Data from Phase 3 Program GlobeNewswire Inc. Jan 14, 04:00 ZORYVE® (Roflumilast) Topical Foam, 0.3% Clears Seborrheic Dermatitis in Individuals Who Previously Reported an Inadequate Response to Topical Steroids GlobeNewswire Inc. Jan 14, 04:00 Majority of Individuals with Atopic Dermatitis Improved with Arcutis’ Roflumilast Cream 0.15% According to New Data from Phase 3 Program GlobeNewswire Inc. Dec 15, 17:11 FDA Approves Arcutis’ ZORYVE® (roflumilast) Topical Foam, 0.3% for the Treatment of Seborrheic Dermatitis in Individuals Aged 9 Years and Older GlobeNewswire Inc. Dec 01, 22:00 Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire Inc. Dec 01, 22:00 Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire Inc. Dec 01, 22:00 Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire Inc. Dec 01, 22:00 Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire Inc. Dec 01, 22:00 Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire Inc. Dec 01, 22:00 Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Benzinga Nov 06, 07:31 DraftKings To Rally Over 48%? Here Are 10 Top Analyst Forecasts For Monday GlobeNewswire Inc. Nov 03, 07:30 Arcutis Announces Third Quarter 2023 Financial Results and Provides Business Update

Revenue Product Segmentation